Holen Sie sich die Stockscreener-App
95.12
0.14%
-0.13
Handel nachbörslich:
96.10
0.98
+1.03%
Schlusskurs vom Vortag:
$95.25
Offen:
$95.6
24-Stunden-Volumen:
6.67M
Relative Volume:
0.85
Marktkapitalisierung:
$139.43B
Einnahmen:
$16.75B
Nettoeinkommen (Verlust:
$1.85B
KGV:
76.10
EPS:
1.25
Netto-Cashflow:
$2.37B
1W Leistung:
+2.68%
1M Leistung:
-3.82%
6M Leistung:
+10.07%
1J Leistung:
+39.96%
1-Tages-Spanne:
$94.67
$96.06
1-Wochen-Bereich:
$91.89
$96.69
52-Wochen-Spanne:
$66.80
$107.17
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Vergleichen Sie BSX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Boston Scientific gets analyst upgrade on Farapulse PFA strength - MassDevice
Should You Buy Boston Scientific Stock Ahead of Q1 Earnings? - Yahoo Finance
Infusion Pumps Market to Soar at a CAGR of ~10% by 2032, Owing to the Advancements in Technology and Increased Demand in Healthcare | DelveInsight - GlobeNewswire Inc.
Boston Scientific Corporation (BSX): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Boston Scientific (NYSE:BSX) Ticks All The Boxes When It Comes To Earnings Growth - Yahoo Finance
Needham Upgrades Boston Scientific (WBAG:BSXC) - Nasdaq
Needham upgrades Boston Scientific on easing competition, growth opportunities - Investing.com
This Boston Scientific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
A Glimpse Into The Expert Outlook On Boston Scientific Through 13 Analysts - Benzinga
Needham raises Boston Scientific stock to Buy, target at $113 - Investing.com
Boston Scientific Corporation (BSX): A Bull Case Theory - Yahoo Finance
RBC Capital maintains Outperform on Boston Scientific, $116 target - Investing.com
Smart Pills Market Detailed In New Research Report 2025 | Boston - openPR.com
A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX) - Yahoo Finance
Truist Lowers Price Target for Boston Scientific (BSX) Ahead of Q1 Results | BSX Stock News - GuruFocus
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance
Boston Scientific Corp. stock rises Friday, still underperforms market - MarketWatch
Boston Scientific price target lowered to $113 from $120 at Truist - TipRanks
Is Boston Scientific Gaining or Losing Market Support? - Benzinga
Boston Scientific (BSX) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
Boston Scientific (BSX) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
FDA clears path for Boston Sci’s Bolt IVL to challenge J&J’s Shockwave - BioWorld MedTech
Lobbying Update: $20,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed - Nasdaq
What to Expect From Boston Scientific’s Q1 2025 Earnings Report - Nasdaq
Boston Scientific (NYSE:BSX) Announces Robust Q4 Results With Increased Sales And Net Income - Yahoo Finance
Interventional Neurology Market Deep Research 2025-2032 | - openPR.com
What To Expect From Boston Scientific’s Q1 2025 Earnings Report - Barchart.com
PFA non-inferior, even superior, to cryoablation for paroxysmal AF - BioWorld MedTech
Boston Scientific Insiders Sell US$1.8m Of Stock, Possibly Signalling Caution - Yahoo Finance
Health Rounds: Some early breast cancers may not need surgery after chemo - MarketScreener
Boston Scientific (BSX) Stock Moves -1.55%: What You Should Know - Yahoo Finance
Tariffs on medical devices could raise healthcare costs - The Business Journals
Boston Scientific Sued Over Endoscopic Medical Device Patent - Bloomberg Law News
Boston Scientific (BSX) Faces Pressure from New Tariffs - GuruFocus
Stryker, Boston Scientific down as new tariffs impact medtech industry - Seeking Alpha
Price Over Earnings Overview: Boston Scientific - Benzinga
Here's Why Boston Scientific (BSX) is a Strong Growth Stock - Yahoo Finance
Is Boston Scientific (NYSE:BSX) A Risky Investment? - Yahoo Finance
Boston Scientific’s Farapulse matches Medtronic cryoablation in trial - Yahoo Finance
Boston Scientific CEO Michael Mahoney sells $16.4 million in stock By Investing.com - Investing.com South Africa
No benefit found for cerebral protection device in TAVR - BioWorld MedTech
Boston Scientific CEO Michael Mahoney sells $16.4 million in stock - Investing.com India
Boston Scientific closes Bolt Medical acquisition - MassDevice
Evercore ISI Adjusts Boston Scientific Price Target to $110 From $112, Maintains Outperform Rating - MarketScreener
Boston Scientific Co. (NYSE:BSX) Shares Purchased by Groupama Asset Managment - MarketBeat
Boston Scientific announces conference call discussing first quarter 2025 results - Quantisnow
FDA Approval Boosts Boston Scientific's (BSX) Investment in Bolt Medical - GuruFocus
FDA clears Bolt Medical’s IVL system, backing Boston Scientific’s $664m buyout - Yahoo Home
Boston Scientific (BSX): Among the Best Healthcare Stocks to Buy According to Billionaires - Insider Monkey
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):